clinical trial · NCT05082662
Bioequivalence Study to Compare Diclofenac Potassium Coated Tablet Versus Cataflam® 50 Coated Tablet
Humanis Saglık Anonim Sirketi·phase2·completed·n = 36
Non-steroidal Anti-inflammatory (NSAID)AnalgesicAntipyreticDiclofenac Potassium coated tablet (50 mg Diclofenac Potassium)Cataflam® 50 coated tablet
brief summary
Randomized, four-way, four-period, fully-replicated, single oral dose, open-label, crossover, bioequivalence study to compare Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium) versus Cataflam® 50 coated tablet (50 mg Diclofenac Potassium), in healthy subjects under fasting condition
started
Aug 25, 2020
primary completion
Sep 16, 2020
completion
Sep 16, 2020
last updated
Dec 13, 2023
official title
Randomized,Fully-replicated,Single Oral Dose,Open-label,Crossover BE Study to Compare Diclofenac Potassium Coated Tablet (50 mg Diclofenac Potassium) Versus Cataflam® 50 Coated Tablet (50 mg Diclofenac Potassium) in Healthy Subjects in Fasting State
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol